arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

IDEAYA Biosciences, Inc.

IDYA Health Care Biotechnology: Pharmaceutical Preparations
$36.12
▲ +2.1% Today
as of Oct 22, 16:49 ET
Last 30 days -5.02% Sep 14 → Oct 22
$32.30 $34.29 $36.28 $38.27 $40.26 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$35.32
High
$36.20
Low
$35.32
Volume
$603,128
Avg Vol
$1M
Mkt Cap
$3.5B
P/E (TTM)
—
Beta
—
52w High
$42.68
52w Low
$26.81
Div Yield
—
Shares Out
$96M

Recent Press Releases & News last 60 days · 13 items

Oct 19 · 15:13 MT Newswires
Ideaya's PRMT5, MAT2A Programs Draw Investor Focus, RBC Says
Oct 19 · 10:00 PR PR Newswire
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
Oct 16 · 11:52 MT Newswires
William Blair Initiates Coverage on IDEAYA Biosciences With Outperform Rating
▸ Show all 13 press releases & news Free account →

IDYA earnings at a glance

IDEAYA Biosciences, Inc. (IDYA) is scheduled to report earnings on Tuesday, November 3, 2026 — in 11 days. Analysts expect earnings per share of -$1.28, compared with $1.33 in the same quarter last year (-196%). The options market is pricing a move of about ±9.2% after the report, a range of roughly $32.81 to $39.43 from today's $36.12. Over its last 6 reports the stock rose the next day 2 times and fell 4, moving ±3.9% on average; after the most recent report on Aug 4, 2026 it moved +2.0%. That means options currently expect more movement than IDYA has typically delivered. IDYA beat the consensus EPS estimate in 1 of its last 5 reported quarters. Implied volatility is currently 77%. The share price of $36.12 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$27
$43
59% of range
Avg surprise (last 5)
-2.2%
Avg reaction (last 6)
-2.7%
33% positive
Latest IV / EM
77%
EM ±9.2% · $35 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.22$-0.58$0.05$0.69$1.33 Actual $-0.49Actual $-0.50Actual $-0.46Actual $-0.53Actual $-0.68Actual $-0.60Actual $-0.82Est $-0.75Actual $-0.88Est $-0.85Actual $1.33Actual $-0.94Est $-1.03Actual $-1.11Est $-1.07Actual $-1.22Est $-1.18 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-112M$-30M$53M$136M$218M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Aug 4, 2026Jun/2026 $-1.22 $-1.18 -3.4% -34.1% +2.0% earnings
Tue May 5, 2026Mar/2026 $-1.11 $-1.07 -3.7% -35.4% -0.3% earnings
Tue Feb 17, 20268K 2026-02-17 $-0.94 $-1.03 +8.7% — +1.6% earnings
Tue Nov 4, 2025Sep/2025 $1.33 — — — -2.8% earnings
Tue Aug 5, 2025Jun/2025 $-0.88 $-0.85 -3.5% — -3.5% earnings
Tue May 6, 2025Mar/2025 $-0.82 $-0.75 -9.3% — -13.3% earnings
Mon Sep 30, 2024Sep 2024 $-0.60 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.68 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.53 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.46 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.50 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.49 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Tue Nov 3, 2026Sep/2026OTHER -$1.28$1.33 -196.2%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$9M$7M—$208M———$0
Cost of revenue————————
Gross profit————————
Operating income$-122M$-109M—$108M$-89M$-84M—$-67M
Net income$-112M$-99M—$119M$-77M$-72M—$-52M
EPS (diluted)$-1.22$-1.11—$1.33$-0.88$-0.82—$-0.60

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$273M$158M$113M$299M$115M$130M$84M$400M
Inventory————————
Total current assets$864M$696M$667M$803M$686M$708M$690M$932M
Total assets$1.31B$1.03B$1.11B$1.19B$1.04B$1.10B$1.12B$1.24B
Long-term debt————————
Total liabilities$111M$93M$86M$93M$82M$77M$65M$59M
Total equity$1.20B$937M$1.02B$1.09B$960M$1.02B$1.06B$1.18B

Implied volatility — last 90 days

26%67%109%150%191% Jun 07 — IV 41% · EM ±5.7%Jun 08 — IV 81% · EM ±10.7%Jun 09 — IV 65% · EM ±8.2%Jun 12 — IV 191% · EM ±19.6%Jun 16 — IV 111% · EM ±6.5%Jun 19 — IV 110% · EM ±24.3%Jun 22 — IV 90% · EM ±18.7%Jun 23 — IV 69% · EM ±14.2%Jun 24 — IV 63% · EM ±12.7%Jun 25 — IV 73% · EM ±14.3%Jun 29 — IV 61% · EM ±10.7%Jun 30 — IV 63% · EM ±10.8%Jul 01 — IV 53% · EM ±8.8%Jul 02 — IV 82% · EM ±13.2%Jul 03 — IV 85% · EM ±13.2%Jul 06 — IV 36% · EM ±5.0%Jul 07 — IV 45% · EM ±5.9%Jul 08 — IV 46% · EM ±5.8%Jul 09 — IV 77% · EM ±9.1%Jul 10 — IV 39% · EM ±4.3%Jul 13 — IV 68% · EM ±5.7%Jul 16 — IV 140% · EM ±5.8%Jul 20 — IV 65% · EM ±15.4%Jul 21 — IV 48% · EM ±11.2%Jul 22 — IV 45% · EM ±10.4%Jul 23 — IV 44% · EM ±9.9%Jul 24 — IV 62% · EM ±13.6%Jul 27 — IV 70% · EM ±14.7%Jul 28 — IV 63% · EM ±12.9%Jul 29 — IV 42% · EM ±8.5%Jul 30 — IV 72% · EM ±14.0%Jul 31 — IV 52% · EM ±10.0%Aug 03 — IV 54% · EM ±9.6%Aug 04 — IV 67% · EM ±11.5%Aug 05 — IV 50% · EM ±8.3%Aug 06 — IV 49% · EM ±8.0%Aug 12 — IV 48% · EM ±6.0%Aug 24 — IV 50% · EM ±10.4%Aug 25 — IV 44% · EM ±9.0%Aug 26 — IV 61% · EM ±12.1%Aug 27 — IV 60% · EM ±11.9%Aug 28 — IV 53% · EM ±10.2%Aug 31 — IV 27% · EM ±4.7%Sep 01 — IV 55% · EM ±9.5%Sep 02 — IV 52% · EM ±8.7%Sep 03 — IV 55% · EM ±8.9%Sep 04 — IV 32% · EM ±5.0%Sep 07 — IV 36% · EM ±5.0%Sep 08 — IV 52% · EM ±6.8%Sep 09 — IV 65% · EM ±8.1%Sep 21 — IV 70% · EM ±14.5%Sep 22 — IV 38% · EM ±7.9%Sep 23 — IV 57% · EM ±11.3%Sep 24 — IV 58% · EM ±11.4%Sep 25 — IV 61% · EM ±11.6%Sep 28 — IV 50% · EM ±8.9%Sep 29 — IV 43% · EM ±7.5%Sep 30 — IV 43% · EM ±7.2%Oct 01 — IV 57% · EM ±9.3%Oct 02 — IV 60% · EM ±9.4%Oct 05 — IV 67% · EM ±9.2%Oct 06 — IV 56% · EM ±7.4%Oct 07 — IV 65% · EM ±8.1%Oct 08 — IV 77% · EM ±9.2%

Sector peers

TNGX
Tango Therapeutics, Inc.
$3.7B $27.93+10.6%
CPRX
Catalyst Pharmaceuticals, Inc.
$3.9B $31.49
RCUS
Arcus Biosciences, Inc.
$3.1B $19.36-18.5%
TLX
Telix Pharmaceuticals Limited
$3.9B $9.54-14.5%
DYN
Dyne Therapeutics, Inc.
$3.0B $15.77-3.1%
ZLAB
Zai Lab Limited
$2.8B $22.04-12.1%

IDYA earnings FAQ

When is IDYA's next earnings date?

IDEAYA Biosciences, Inc. is expected to report on November 3, 2026.

What is IDYA's expected move for earnings?

Options currently price a move of about ±9.2%, or $3.31 per share either way from $36.12.

How does IDYA stock usually react to earnings?

Across the last 6 reports the average next-day move was ±3.9%, up 2 times and down 4 times.

What EPS are analysts expecting from IDEAYA Biosciences, Inc.?

The consensus estimate is -$1.28 per share, versus $1.33 a year ago.

What is IDYA's implied volatility?

IDYA's at-the-money implied volatility is about 77% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in